Showing 5,821 - 5,840 results of 9,936 for search 'chav~', query time: 1.88s Refine Results
  1. 5821
  2. 5822
  3. 5823
  4. 5824
  5. 5825
  6. 5826
  7. 5827
  8. 5828
  9. 5829
  10. 5830
  11. 5831
  12. 5832
  13. 5833
  14. 5834
  15. 5835
  16. 5836

    Welfare of horses during killing for purposes other than slaughter by EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), Søren Saxmose Nielsen, Julio Alvarez, Anette Boklund, Sabine Dippel, Fernanda Dorea, Jordi Figuerola, Mette Herskin, Miguel Angel Miranda Chueca, Eleonora Nannoni, Romolo Nonno, Anja Riber, Karl Stahl, Jan Arend Stegeman, Hans‐Hermann Thulke, Frank Tuyttens, Christoph Winckler, Mohan Raj, Antonio Velarde, Denise Candiani, Yves Van der Stede, Virginie Michel

    Published 2025-01-01
    “…Abstract Horses of different ages may have to be killed on‐farm for purposes other than slaughter (where slaughter is defined as killing for human consumption) either individually (i.e. on‐farm killing of unproductive, injured or terminally ill animals) or on a large‐scale (i.e. depopulation for disease control purposes and other situations, such as environmental contamination, disaster management, etc.). …”
    Get full text
    Article
  17. 5837
  18. 5838

    Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials by Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J. Gordon, Nadine Rouphael, Katherine V. Houser, Emily E. Coates, Barney S. Graham, Richard A. Koup, John R. Mascola, Nancy J. Sullivan, Merlin L. Robb, Julie A. Ake, Kirsten E. Lyke, Mark J. Mulligan, Julie E. Ledgerwood, Hannah Kibuuka, the VRC 208 and RV 422 study team

    Published 2024-03-01
    “…We investigated the safety and immunogenicity of a heterologous prime-boost regimen involving a chimpanzee adenovirus 3 vectored Ebola vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed by a recombinant modified vaccinia virus Ankara EBOV vaccine (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials in healthy adults in the United States (US) and Uganda (UG). …”
    Get full text
    Article
  19. 5839
  20. 5840